Cargando…
Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian...
Autores principales: | Murray, Jackelyn, Hogan, Robert J., Martin, David E., Blahunka, Kathy, Sancilio, Fred D., Balyan, Rajiv, Lovern, Mark, Still, Richard, Tripp, Ralph A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8433326/ https://www.ncbi.nlm.nih.gov/pubmed/34508172 http://dx.doi.org/10.1038/s41598-021-97658-w |
Ejemplares similares
-
Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication
por: Murray, Jackelyn, et al.
Publicado: (2022) -
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication
por: Tripp, Ralph A., et al.
Publicado: (2022) -
Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19
por: Martin, David E., et al.
Publicado: (2023) -
Drug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro
por: Orr-Burks, Nichole, et al.
Publicado: (2021) -
Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2
por: Iwanaga, Naoki, et al.
Publicado: (2020)